Login to Your Account



Santhera, Ipsen Sign $181M Collaboration for Fipamezole

By Cormac Sheridan


Wednesday, September 8, 2010
Shares in Santhera Pharmaceuticals AG rose more than 8 percent Friday on news of a European partnering deal with Ipsen Group SA, worth up to €141 million (US$181 million), for its Parkinson's drug Fipamezole. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription